TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04429100

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
Study: NCT06577727

Intervention type: OTHER
Intervention: Gold standard blood test
Description: Blood test will measure haemoglobin and other parameters

Intervention type: OTHER
Intervention: Imaging and videography of anatomical sites
Description: Images and videos of anatomical sites will be collected for AI to estimate iron status
Study: NCT06578325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai dance meditation
Description: Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2.... Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT05646264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
Study: NCT04487756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: - Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADC Vaccine
Description: - Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
Study: NCT05662254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Intervention
Description: Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
Study: NCT06118372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor
Description: Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
Study: NCT05408208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Injection of Methotrexate
Description: One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Injection of Methotrexate
Description: One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonid
Description: One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonid
Description: One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
Study: NCT05561270

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: White LED light
Description: Exposure to white LED light for 1-2 hours/day x 10 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green LED light
Description: Exposure to green LED light for 1-2 hours/day x 10 weeks
Study: NCT06093113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alba - Youth in grief
Description: The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
Study: NCT01170871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT04941612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa IM-Nail
Description: PLGA bioabsorbable intramedullary nail
Study: NCT05703178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Pain Coping Skills Training
Description: The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
Study: NCT05737381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Differential oxygen tension
Description: By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
Study: NCT06093113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control website
Description: The website will contain information about grief and grief reactions similar to some of the information given in the app.
Study: NCT06516497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group using traditional method in long bone deformity correction
Description: Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using computer-aided sensors in long bone deformity correction
Description: After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
Study: NCT06129344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage Group
Description: Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy group
Description: Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
Study: NCT06176066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEST PH MRI based resection of glioblastoma
Description: Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
Study: NCT04541147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)
Study: NCT06386523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passage of olfactory tests
Description: test TODA2 and Sniffin Stick Test
Study: NCT06636409

Intervention type: OTHER
Intervention: Collection of medical data
Description: A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
Study: NCT06636461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfragmented adipose tissue loaded on allograft
Description: microfragmented adipose tissue loaded on allograft on ridge preservation
Study: NCT04487756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
Study: NCT04965220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX 208
Description: take orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX 208
Description: take orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX 208
Description: take orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX 208
Description: take orally
Study: NCT06636461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfragmented adipose tissue loaded on allograft
Description: microfragmented adipose tissue loaded on allograft on ridge preservation
Study: NCT06635369

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Indices
Description: Saliva, serum and periodontal indexes were obtained from patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Indices
Description: Saliva, serum and periodontal indexes were obtained from patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Indices
Description: Saliva, serum and periodontal indexes were obtained from patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Indices
Description: Saliva, serum and periodontal indexes were obtained from patients
Study: NCT06378346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: 75mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: 75mg orally daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glycyrrhizin
Description: 150mg orally daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Participants will not receive any Glycyrrhizin
Study: NCT05720949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genicular Nerve Block with bupivacaine and preservative free dexamethasone
Description: A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid
Study: NCT05893758

Intervention type: DEVICE
Intervention: The Cera™ PFO Occluder
Description: The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
Study: NCT06043323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given by IV (vein)
Study: NCT04559789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindMate + Health Coaching
Description: The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education materials delivered electronically
Study: NCT05801536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCONE
Description: This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
Study: NCT05989256

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EndoTool
Description: EndoTool is a vendor based glucose management software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose management team
Description: comparison group will be services that have not yet implemented EndoTool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care glucose management
Description: providers adjusting insulin and consulting the Glucose Management Team at their discretion
Study: NCT06283836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: monitored anesthesia care (sedation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: monitored anesthesia care (sedation)
Study: NCT05633160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-BBN
Description: 64Cu-SAR-BBN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67Cu-SAR-BBN
Description: 67Cu-SAR-BBN
Study: NCT06457802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less Program
Description: The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
Study: NCT06369454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
Study: NCT04391023

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance Training
Description: The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mA Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
Study: NCT06003478

Intervention type: PROCEDURE
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
Description: Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
Study: NCT05172856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI321
Description: IBI321 at a dose no higher than RP2D, D1 IV Q3W.